Search results
Kyowa Kirin is a Japan-based company that develops innovative drugs for various diseases and conditions. Learn about its philosophy, history, network, products, and stories on its corporate website.
- What we do
Through a robust pipeline of promising drug candidates,...
- Sustainability
Our Impact Kyowa Kirin practices CSV management aimed at...
- Stories
Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical...
- Media Center
The global speciality pharmaceutical innovator, Kyowa Kirin...
- What we do
Kyowa Kirin Co., Ltd. (協和キリン株式会社, Kyōwa Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue.
Kyowa Kirin is a Japanese pharma group that develops innovative specialty drugs. Learn about its history, business, capital, employees and headquarters.
Kyowa Kirin is a Japan-based company that develops and commercializes innovative drugs in oncology, nephrology, CNS and immunology. It uses cutting-edge biotechnology, such as antibody engineering, small molecule drugs and nucleic acid drugs, and collaborates with partners worldwide.
Kyowa Kirin pursues scientific breakthroughs to address unmet clinical needs. Learn more about our portfolio of specialty medicines in nephrology, oncology, immunology & allergy, and neurology. Join us to grow your career or partner with us to propel your research discoveries into the hands of patients and physicians.
May 31, 2024 · This is the Kirin Holdings Kyowa Kirin page under the Pharmaceuticals domain page. It includes the specific business activities and product brands in the three main domains of the Kirin Group (Food & Beverages, Health Science and Pharmaceuticals).
People also ask
What does Kyowa Kirin stand for?
What does Kyowa Kirin do?
What makes Kyowa Kirin a great company?
Who is Kyowa Hakko Kirin?
Jan 1, 2024 · Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2024 First Quarter (1,259KB). Results Presentation Fiscal 2024 First Quarter (880KB). Transcript of Results Briefing Fiscal 2024 First Quarter (1,535KB). more.